Molecular pathways in cardiovascular disease under hypoxia: Mechanisms, biomarkers, and therapeutic targets

Area of Science:

• Cardiovascular Biology
• Mitochondrial Medicine
• Cellular Physiology

Background:

• Chronic hypoxia is a major driver of cardiovascular diseases, including ischemia, heart failure, and hypertension.
• Oxygen deficiency under hypoxia disrupts mitochondrial ATP production and increases reactive oxygen species (ROS).
• This leads to mitochondrial dysfunction, oxidative stress, calcium imbalance, and apoptosis.

Purpose of the Study:

• To review the molecular mechanisms of hypoxia-induced cardiovascular diseases.
• To focus on mitochondrial impairment, ion channel dysfunction, and ROS production.
• To explore therapeutic strategies targeting these pathways.

Main Methods:

• Literature review focusing on molecular mechanisms.
• Analysis of mitochondrial K-ATP (mitoK-ATP) and mitochondrial permeability transition pore (mPTP) channel roles.
• Examination of hypoxia-inducible factor 1-alpha (HIF-1α) as a biomarker.

Main Results:

• Hypoxia-induced ROS and mitochondrial dysfunction contribute to cell death via mPTP opening and cytochrome C release.
• Mitochondrial ion channels (mitoK-ATP, mPTP) are critical targets in hypoxia.
• HIF-1α is a key biomarker for cellular adaptation to hypoxia.

Conclusions:

• Therapeutic strategies involving antioxidants and ion channel modulators (K-ATP, mPTP) can mitigate hypoxia-induced cardiovascular damage.
• Integrated approaches using in vitro, in vivo, and in silico studies are crucial for developing novel therapies.
• Preserving mitochondrial integrity is key to preventing and treating hypoxia-related cardiovascular diseases.